Focus: Bioventus is a publicly traded orthobiologics company focused on musculoskeletal pain management, operating at mid-cap scale with ~1,000-5,000 employees and $512M in annual revenue.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Bioventus to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Bioventus's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for Bioventus
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Musculoskeletal Pain Market Poised for Transformation During the Forecast Period (2026-2036) as Novel Therapies and Non-Opioid Approaches Reshape Treatment | DelveInsight - PR Newswire
Musculoskeletal Pain Market Poised for Transformation During the Forecast Period (2026-2036) as Novel Therapies and Non-Opioid Approaches Reshape Treatment | DelveInsight PR Newswire
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
Are Medical Stocks Lagging Bioventus (BVS) This Year? Yahoo Finance
Bioventus Starts Review After Unsolicited Acquisition Proposal - Stock Titan
Bioventus Starts Review After Unsolicited Acquisition Proposal Stock Titan
Bioventus schedules Aug. 5 call to discuss second-quarter results - Stock Titan
Bioventus schedules Aug. 5 call to discuss second-quarter results Stock Titan
Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth - Yahoo Finance
Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth Yahoo Finance
8-K Filing: AVANOS MEDICAL, INC. (AVNS) (CIK 0001606498) — 8-K
8-K
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Systematic evaluation of surgical insertion of flexible neural probe arrays into deeper brain targets using length modulation methods.
Composition and Bioactivity of a Placental Tissue Particulate (PTP-001) Indicate Greater Potential than Platelet-Rich Plasma for the Treatment of Osteoarthritis.
Showing 5 of 10 publications